Vis enkel innførsel

dc.contributor.authorGiskeødegård, Guro F.
dc.contributor.authorMadssen, Torfinn Støve
dc.contributor.authorSangermani, Matteo
dc.contributor.authorLundgren, Steinar
dc.contributor.authorWethal, Torgeir
dc.contributor.authorAndreassen, Trygve
dc.contributor.authorReidunsdatter, Randi Johansen
dc.contributor.authorBathen, Tone Frost
dc.date.accessioned2023-01-31T15:40:01Z
dc.date.available2023-01-31T15:40:01Z
dc.date.created2022-10-11T15:13:40Z
dc.date.issued2022
dc.identifier.citationFrontiers in Oncology. 2022, 12 .en_US
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/11250/3047500
dc.description.abstractThe multimodal treatment of breast cancer may induce long term effects on the metabolic profile and increase the risk of future cardiovascular disease. In this study, we characterized longitudinal changes in serum lipoprotein subfractions and metabolites after breast cancer treatment, aiming to determine the long-term effect of different treatment modalities. Further, we investigated the prognostic value of treatment-induced changes in breast cancer-specific and overall 10-year survival. In this study, serum samples from breast cancer patients (n = 250) were collected repeatedly before and after radiotherapy, and serum metabolites and lipoprotein subfractions were quantified by NMR spectroscopy. Longitudinal changes were assessed by univariate and multivariate data analysis methods applicable for repeated measures. Distinct changes were detectable in levels of lipoprotein subfractions and circulating metabolites during the first year, with similar changes despite large differences in treatment regimens. We detect increased free cholesterol and decreased esterified cholesterol levels of HDL subfractions, a switch towards larger LDL particles and higher total LDL-cholesterol, in addition to a switch in the glutamine-glutamate ratio. Non-survivors had different lipid profiles from survivors already at baseline. To conclude, our results show development towards an atherogenic lipid profile in breast cancer patients with different treatment regimens.en_US
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleLongitudinal Changes in Circulating Metabolites and Lipoproteins After Breast Cancer Treatmenten_US
dc.title.alternativeLongitudinal Changes in Circulating Metabolites and Lipoproteins After Breast Cancer Treatmenten_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber12en_US
dc.source.volume12en_US
dc.source.journalFrontiers in Oncologyen_US
dc.identifier.doi10.3389/fonc.2022.919522
dc.identifier.cristin2060575
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal